 Vincristine
"Vincristine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
| Descriptor ID |
D014750
|
| MeSH Number(s) |
D03.132.436.681.827.817 D03.633.100.473.402.681.827.817
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Vincristine".
Below are MeSH descriptors whose meaning is more specific than "Vincristine".
This graph shows the total number of publications written about "Vincristine" by people in this website by year, and whether "Vincristine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 | | 1996 | 0 | 1 | 1 | | 1997 | 0 | 1 | 1 | | 1998 | 0 | 2 | 2 | | 2000 | 1 | 0 | 1 | | 2001 | 0 | 2 | 2 | | 2002 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2006 | 0 | 1 | 1 | | 2009 | 1 | 1 | 2 | | 2010 | 0 | 2 | 2 | | 2011 | 1 | 3 | 4 | | 2012 | 0 | 2 | 2 | | 2014 | 0 | 3 | 3 | | 2015 | 0 | 3 | 3 | | 2016 | 1 | 2 | 3 | | 2017 | 0 | 4 | 4 | | 2018 | 1 | 2 | 3 | | 2019 | 0 | 4 | 4 | | 2020 | 1 | 2 | 3 | | 2021 | 1 | 4 | 5 | | 2022 | 0 | 2 | 2 | | 2023 | 0 | 4 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Vincristine" by people in Profiles.
-
Borst AJ, Eng W, Griffin M, Ricci KW, Engel E, Adams DM, Dayneka J, Cohen-Cutler SJ, Andreoli SM, Wu MD, Wheeler AP, Heym KM, Crary SE, Nakano TA, Schulte RR, Setty BA, McLean TW, Pahl KS, Intzes S, Pateva I, Teitelbaum M, Zong Z, Li Y, Jeng MR. Treatment practices and response in kaposiform hemangioendothelioma: A multicenter cohort study. Pediatr Blood Cancer. 2024 Mar; 71(3):e30779.
-
Luna-Fineman S, Castellanos M, Metzger ML, Baez LF, Pe?a Hernandez A, Bonilla M, Fuentes-Alabi S, Nieves R, Blanco J, Rossi E, Devidas M, Chen Y, Arreola M, de Alarcon PA. Treatment of high-risk Hodgkin lymphoma with a modified Stanford V regimen in the AHOPCA: Substituting chemotherapy agents and hampered outcomes. Pediatr Blood Cancer. 2024 Feb; 71(2):e30792.
-
Zayac AS, Landsburg DJ, Hughes ME, Bock AM, Nowakowski GS, Ayers EC, Girton M, Hu M, Beckman AK, Li S, Medeiros LJ, Chang JE, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi YH, Epperla N, Bond DA, Farooq U, Saad M, Evens AM, Pandya K, Naik SG, Kamdar M, Haverkos B, Karmali R, Oh TS, Vose JM, Nutsch H, Rubinstein PG, Chaudhry A, Olszewski AJ. High-grade B-cell lymphoma, not otherwise specified: a?multi-institutional retrospective study. Blood Adv. 2023 11 14; 7(21):6381-6394.
-
Graff Z, Giron V, Miller K, Pixtun D, Alejos A, Luna-Fineman S. Toxicity and feasibility of vincristine, etoposide, and carboplatin alternating with vincristine, doxorubicin, and cyclophosphamide in children with advanced retinoblastoma in Guatemala. Pediatr Blood Cancer. 2023 07; 70(7):e30392.
-
Cortese MJ, Wei W, Cerde?a S, Watkins MP, Olson M, Jodon G, Kaiser J, Haverkos B, Hughes ME, Namoglu E, Grover NS, Snow A, Orellana-Noia V, Rainey M, Sohail M, Rudoni J, Portell C, Voorhees T, Landsburg DJ, Kamdar M, Kahl BS, Hill BT. A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma. Leuk Lymphoma. 2023 01; 64(1):107-118.
-
Iguchi N, Hecht SL, Gao D, Wilcox DT, Malykhina AP, Cost NG. Sexual dimorphic impacts of systemic vincristine on lower urinary tract function. Sci Rep. 2022 03 24; 12(1):5113.
-
Major A, Smith SM. DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose? Clin Adv Hematol Oncol. 2021 Nov; 19(11):698-709.
-
Hecht SL, Quach A, Gao D, Brazell A, Beltran G, Holbrook S, Gore L, Iguchi N, Malykhina A, Wilcox D, Cost NG. A prospective survey study of lower urinary tract dysfunction in childhood cancer survivors after vincristine and/or doxorubicin chemotherapy. Pediatr Blood Cancer. 2021 10; 68(10):e29226.
-
Svoboda J, Bair SM, Landsburg DJ, Dwivedy Nasta S, Nagle SJ, Barta SK, Khan N, Filicko-O'Hara J, Gaballa S, Strelec L, Chong E, Mitnick S, Waite TS, King C, Ballard H, Youngman M, Gerson J, Plastaras JP, Maity A, Bogusz AM, Hung SS, Nakamura H, Nejati R, Steidl C, Lim M, Ruella M, Schuster SJ. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. Haematologica. 2021 06 01; 106(6):1705-1713.
-
Chien HC, Morreall D, Patil V, Rasmussen KM, Yong CM, Li CY, Passey DG, Burningham Z, Sauer BC, Halwani AS. Real-world treatment patterns and outcomes in a national study of veterans with Waldenstr?m macroglobulinemia, 2006-2019. Am J Hematol. 2021 06 01; 96(6):E184-E187.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|